Development and characterization of glutathione-conjugated albumin nanoparticles for improved brain delivery of hydrophilic fluorescent marker

Drug Delivery

Volumn 20, Issue 3-4, 2013, Pages 143-155

  Patel, Prerak J ^a   Acharya, Niyati S ^a   Acharya, Sanjeev R ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

Albumin nanoparticles; Biodistribution; Blood brain barrier; Glutathione

Indexed keywords

ALBUMIN CONJUGATE; CYANAMIDE; FLUORESCEIN SODIUM; GLUTATHIONE; NANOPARTICLE;

ANIMAL CELL; ARTICLE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; ENDOTHELIUM CELL; GLUTATHIONE METABOLISM; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROSCOPE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN; CATTLE; COCULTURE TECHNIQUES; DOGS; DRUG DELIVERY SYSTEMS; FLUORESCENT DYES; GLUTATHIONE; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MALE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; SERUM ALBUMIN, BOVINE;

EID: 84879020631     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.801050     Document Type: Article

References (62)

1. Acharya S, Sahoo S.K. (2011). PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 63:170-83
2. Bagger MA, Bechgaard E. (2004). The potential of nasal application for delivery to the central brain-A microdialysis study of fluorescein in rats. Eur J Pharm Sci 21:235-42 (Pubitemid 38156160)
3. Banks WA. (2012). Drug delivery to the brain in Alzheimer's disease: Consideration of the blood-brain barrier. Adv Drug Deliv Rev 64: 629-39
4. Benarroch EE. (2010). Glutamate transporters: Diversity, function, and involvement in neurologic disease. Neurology 74:259-64
5. Benarroch EE. (2012). Blood-brain barrier. Neurology 78:1268-76
6. Bernkop-Schnurch A, Kast CE, Guggi D. (2003). Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: Thiomer/ GSH systems. J Control Release 93:95-103 (Pubitemid 37421352)
7. Bernkop-Schnurch A, Steininger S. (2000). Synthesis and characterisation of mucoadhesive thiolated polymers. Int J Pharm 194:239-47 (Pubitemid 30110686)
8. Bowman GL, Kaye JA, Moore M, et al. (2007). Blood-brain barrier impairment in Alzheimer disease: Stability and functional significance. Neurology 68:1809-14 (Pubitemid 46791393)
9. Catuogno S, Esposito CL, Quintavalle G, et al. (2012). Nucleic Acids in human glioma treatment: Innovative approaches and recent results. J Signal Transduct 11:1-11
10. Chakraborty SP, Das S, Chattopadhyay S, et al. (2012). Staphylococcus aureus infection induced redox signaling and DNA fragmentation in T-lymphocytes: Possible ameliorative role of nanoconjugated vancomycin. Toxicol Mech Methods 22:193-204
11. Chin TY, Chueh SH, Tao PL. (2006). S-Nitrosoglutathione and glutathione act as NMDA receptor agonists in cultured hippocampal neurons. Acta Pharmacol Sin 27:853-60
12. Dringen R, Hirrlinger J. (2003). Glutathione pathways in the brain. Biol Chem 384:505-16 (Pubitemid 36609167)
13. Elsabahy M, Wooley KL. (2012). Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev 41:2545-61
14. Fluorescein Novartis [Online]. Available from: Http://www.betterhealth.- vic.gov.au/bhcv2/bhcmed.nsf/pages/nvcfluin/$File/nvcfluin.pdf [last accessed 8 Jan 2013].
15. Freytag T, Dashevsky A, Tillman L, et al. (2000). Improvement of the encapsulation efficiency of oligonucleotide-containing biodegradable microspheres. J Control Release 69:197-207
16. Gaillard PJ, Appeldoorn CC, Rip J, et al. (2012). Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J Control Release 164: 364-9
17. Garberg P, Ball M, Borg N, et al. (2005). In vitro models for the blood-brain barrier. Toxicol In Vitro 19:299-334 (Pubitemid 40248750)
18. Geldenhuys W, Mbimba T, Bui T, et al. (2011). Brain-Targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers. J Drug Target 19:837-45
19. Govender T, Stolnik S, Garnett MC, et al. (1999). PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug. J Control Release 57:171-85 (Pubitemid 29062869)
20. Guo P, Weinstein AM, Weinbaum S. (2003). A dual-pathway ultrastructural model for the tight junction of rat proximal tubule epithelium. Am J Physiol Renal Physiol 285:F241-57 (Pubitemid 36871196)
21. he C, Hu Y, Yin L, et al. (2010). Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31:3657-66
22. Jain A, Chourasia MK, Soni V, et al. (2006). Brain-specific delivery of rifampin from lactyl stearate-coupled liposomes via monocarboxylic acid transporters. Adv Drug Deliv Rev 4:43-9
23. Jayant RD, Srivastava R. (2007). Dexamethasone release from uniform sized nanoengineered alginate microspheres. J Biomed Nanotechnol 3:245-53 (Pubitemid 351877150)
24. Jiao H, Wang Z, Liu Y, et al. (2011). Specific role of tight junction proteins claudin-5, occludin, and ZO-1 of the blood-brain barrier in a focal cerebral ischemic insult. J Mol Neurosci 44:130-9
25. Jin X, Xu Y, Shen J, et al. (2011). Chitosan-glutathione conjugate-coated poly(butyl cyanoacrylate) nanoparticles: Promising carriers for oral thymopentin delivery. Carbohydrate Polymers 86:51-7
26. Jun JY, Nguyen HH, Paik S-Y-R, et al. (2011). Preparation of sizecontrolled bovine serum albumin (BSA) nanoparticles by a modified desolvation method. Food Chem 127:1892-8
27. Kakran M, Sahoo NG, Li L, Judeh Z. (2010). Dissolution of artemisinin/ polymer composite nanoparticles fabricated by evaporative precipitation of nanosuspension. J Pharm Pharmacol 62:413-21
28. Kannan R, Kuhlenkamp JF, Jeandidier E, et al. (1990). Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. J Clin Invest 85:2009-13 (Pubitemid 20192980)
29. Kannan R, Kuhlenkamp JF, Ookhtens M, Kaplowitz N. (1992). Transport of glutathione at blood-brain barrier of the rat: Inhibition by glutathione analogs and age-dependence. J Pharmacol Exp Ther 263:964-70 (Pubitemid 23157167)
30. Kashi TS, Eskandarion S, Esfandyari-Manesh M, et al. (2012). Improved drug loading and antibacterial activity of minocycline-loaded PLGA nanoparticles prepared by solid/oil/water ion pairing method. Int J Nanomedicine 7:221-34
31. Kratzer I, Wernig K, Panzenboeck U, et al. (2007). Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J Control Release 117:301-11 (Pubitemid 46216580)
32. Krizbai IA, Deli MA, Pestenacz A, et al. (1998). Expression of glutamate receptors on cultured cerebral endothelial cells. J Neurosci Res 54: 814-19 (Pubitemid 28544382)
33. Kumari A, Yadav SK, Yadav SC. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. Coll Surf B: Biointerfaces 75:1-18
34. Lalo U, Pankratov Y, Kirchhoff F, et al. (2006). NMDA receptors mediate neuron-To-glia signaling in mouse cortical astrocytes. J Neurosci 26:2673-83 (Pubitemid 43357850)
35. Lamprecht A, Ubrich N, Hombreiro Perez M, et al. (2000). Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. Int J Pharm 196: 177-82 (Pubitemid 30105738)
36. Leung JC, Travis BR, Verlander JW, et al. (2002). Expression and developmental regulation of the NMDA receptor subunits in the kidney and cardiovascular system. Am J Physiol Regul Integr Comp Physiol 283:R964-71
37. Lindqvist A, Rip J, Gaillard PJ, et al. (2012). Enhanced brain delivery of the opioid peptide DAMGO in glutathione PEGylated liposomes: A microdialysis study. Mol Pharm 14:14-24
38. Liu X, Chen C. (2005). Strategies to optimize brain penetration in drug discovery. Curr Opin Drug Discov Devel 8:505-12 (Pubitemid 40917412)
39. Lu W, Zhang Y, Tan YZ, et al. (2005). Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release 107:428-48 (Pubitemid 41393353)
40. Mailander V, Landfester K. (2009). Interaction of nanoparticles with cells. Biomacromolecules 10:2379-400
41. Martin HL, Teismann P. (2009). Glutathione-A review on its role and significance in Parkinson's disease. FASEB J 23:3263-72
42. McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS. (2012). Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: Safety and efficacy evaluation in Rhesus Macaques. Cancer Res 72:3652-63
43. Mittnacht U, Hartmann H, Hein S, et al. (2010). Chitosan/siRNA nanoparticles biofunctionalize nerve implants and enable neurite outgrowth. Nano Lett 10:3933-9
44. Muro K, Das S, Raizer JJ. (2006). Convection-enhanced and local delivery of targeted cytotoxins in the treatment of malignant gliomas. Technol Cancer Res Treat 5:201-13 (Pubitemid 43946254)
45. Nobs L, Buchegger F, Gurny R, Allemann E. (2003). Surface modification of poly(lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods. Int J Pharm 250:327-37 (Pubitemid 36084357)
46. Pardridge WM. (2005). Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems. Int Congress Series 1277:49-62 (Pubitemid 44262151)
47. Patel P, Acharya S. (2012). Design and development of glutathione conjugated poly(d, l) lactide nanocarriers for delivery of hydrophilic fluorescent marker across blood brain barrier. Curr Nanosci 8:847-57
48. Patel P, Acharya N, Acharya S. (2011). Potential of surface functionalized nanoparticles for improved therapy of refractory CNS disorders. J Pharmacy Res 4:1093-9
49. Peltonen L, Aitta J, Hyvonen S, et al. (2004). Improved entrapment efficiency of hydrophilic drug substance during nanoprecipitation of poly(l)lactide nanoparticles. AAPS PharmSciTech 5:115-20
50. Rao KS, Reddy MK, Horning JL, Labhasetwar V. (2008). TATconjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 29:4429-38
51. Reijerkerk A, Kooij G, Van Der Pol SM, et al. (2010). The NR1 subunit of NMDA receptor regulates monocyte transmigration through the brain endothelial cell barrier. J Neurochem 113:447-53
52. Smith QR. (2005). Carrier-mediated transport to enhance drug delivery to brain. Int Congress Series 1277:63-74 (Pubitemid 43693331)
53. Sunitha R, Harika D, Phani A, et al. (2011). A review: Nanoparticles as specified carriers in targeted brain drug delivery system. Am J Pharmaceut Technol Res 1:121-34
54. Uchida T, Yoshida K, Goto S. (1996). Preparation and characterization of polylactic acid microspheres containing water-soluble dyes using a novel w/o/w emulsion solvent evaporation method. J Microencapsul 13:219-28
55. Umnarat S. (2006). Brain delivery enhancement of curcumin via nanotechnology [thesis]. Mahidol University
56. Wilson B, Samanta MK, Santhi K, et al. (2008). Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res 20:159-68
57. Witschi C, Doelker E. (1998). Influence of the microencapsulation method and peptide loading on poly(lactic acid) and poly(lactic-coglycolic acid) degradation during in vitro testing. J Control Release 51:327-41 (Pubitemid 28252884)
58. Yang R, Yang SG, Shim WS, et al. (2009). Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J Pharm Sci 98:970-84
59. Yu MK, Park J, Jon S. (2012). Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2:3-44
60. Zhang Y, Huo M, Zhou J, et al. (2010). DDSolver: An add-in program for modeling and comparison of drug dissolution profiles. AAPS J 12: 263-71
61. Zhao D, Zhao X, Zu Y, et al. (2010). Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomedicine 5:669-77
62. Zlokovic BV, Mackic JB, McComb JG, et al. (1994). Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain. Biochem Biophys Res Commun 201:402-8 (Pubitemid 24213740)